Author: Nat Pernick, M.D.

Revised: 30 March 2018, last major update February 2013

Copyright: (c) 2003-2018,, Inc.

PubMed Search: brca2[title]
Cite this page: Pernick, N. BRCA2. website. Accessed October 21st, 2018.
Definition / general
  • Tumor suppressor gene at 13q12-13; considered a "caretaker" gene that maintains stability in the cellular network, rather than a "gatekeeper" gene that directly inhibits cell growth or promotes cell death (OMIM 600185)
  • Interacts with RAD51; may facilitate homologous recombination in bypass of stalled replication forks
  • Loss of functional BRCA1 or BRCA2 leads to activation of p53, causing cell cycle arrest or apoptosis
  • If p53 if inactivated, proliferation results in progressive accumulation of DNA damage and increased frequency of malignancy
  • 6174delT in BRCA2 common in Ashkenazi Jews
  • BRCA1 and BRCA2 mutations in Ashkenazi Jews have 2% prevalence vs. 0.1% of rest of population
  • Gene first cloned at Myriad Genetics, and the subject of extensive patent litigation (Wikipedia)

  • See also BRCA2 associated breast carcinoma
  • Patients with BRCA1 or BRCA2 mutation have a 35%-80% lifetime risk of breast cancer by age 70; usually high grade, aneuploid, but ER+, PR+ (Mod Pathol 2005;18:1305)
  • Higher risk with 4486 G > T mutation
  • Men with BRCA2 mutation have higher risk of breast cancer also

  • 15%-27% lifetime risk of adenocarcinoma in women with mutations
  • Often younger patients with high stage tumors
  • BRCA mutations cause 90% of hereditary cases of ovarian carcinomas, which account for 10% of all ovarian carcinomas (Hum Pathol 2005;36:861)
  • For patients with known BRCA1 or BRCA2 mutation or family history of breast or ovarian cancer, should submit entire fallopian tube and ovary for microscopic examination Am J Surg Pathol 2002;26:171, Am J Surg Pathol 2001;25:1283), as incidental neoplasms are common (Am J Surg Pathol 2006;30:1222)

Diagrams / tables

Images hosted on other servers:

Role in DNA Repair

Uses by pathologists
  • Genetic testing is important, since prophylactic oophorectomy and rigorous breast surveillance is recommended for BRCA1 or BRCA2 mutation carriers when childbearing is completed (BMC Womens Health 2010 Oct 20;10:28); risk-reducing salpingo-oophorectomy (RRSO) causes a 72% reduction in BRCA2-associated breast cancer risk without significant reduction in BRCA2-associated gynecologic cancer risk (Arch Pathol Lab Med 2009;133:1041)
Microscopic (histologic) images

Images hosted on other servers:

Breast: normal and hereditary cancer

Ovarian carcinoma,
endometrioid type: BRCA2
and AURKA expression

Prostate carcinoma,
endometrioid type: BRCA2
and AURKA expression

Positive staining - normal
  • Keratinizing squamous epithelium, breast, prostate (nuclei of both luminal and basal epithelial layers in normal tissue and BPH)
Negative staining